Therapeutic vaccines for XXXX .

@entity11 @entity1 @entity5 @entity1313
@entity11 are the most common and aggressive form of @entity1313 . Current therapy consists of surgical resection, followed by radiation therapy and concomitant chemotherapy. Despite these treatments, the prognosis for @entity1 is poor. As such, investigative therapies including @entity5 vaccines have targeted this devastating condition. Recent clinical trials involving immunotherapy, specifically dendritic cell (DC) based vaccines, have shown promising results. Overall, these vaccines are well tolerated with few documented side effects. In many @entity1 receiving vaccines, @entity5 progression was delayed and the median overall survival of these @entity1 was prolonged. Despite these encouraging results, several factors have limited the efficacy of DC vaccines. Here we discuss the potential of DC vaccines as adjuvant therapy and current obstacles of generating highly pure and potent DC vaccines in the context of @entity11 . Taken together, the results from earlier clinical studies justify additional clinical trials aimed at improving the efficacy of DC vaccines.
